Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Incidence of Second-line advanced biliary tract cancer
8 evidence topics · 8 sources
Summary: incidence of biliary tract cancer and of the second-line population
No registry reports the incidence of second-line advanced biliary tract cancer directly; it is estimated from the incidence of biliary tract cancer and the proportion of participants who reach a second line of therapy. For 2026, the American Cancer Society estimates 42,340 new cases of liver and intrahepatic bile duct cancer and 12,640 new cases of gallbladder and other biliary cancer in the United States. Compass Therapeutics estimates approximately 26,500 people newly diagnosed with biliary tract cancer in the United States each year and over 200,000 worldwide.
In the Surveillance, Epidemiology, and End Results program, the overall age-adjusted incidence of cholangiocarcinoma from 2001 to 2017 was 3.65 per 100 000 person-years and rose 43.8% over that period, driven by a 148.8% rise in intrahepatic cholangiocarcinoma against a 7.5% rise in extrahepatic cholangiocarcinoma. In North American Association of Central Cancer Registries data for 1999 to 2013, intrahepatic and extrahepatic cholangiocarcinoma rates increased by 3.2% and 1.8% per year while gallbladder cancer rates declined among women and among people aged 45 years or older. Globally, GLOBOCAN 2024 estimated 126,384 new gallbladder cancers and 843,045 new cancers of the liver and intrahepatic bile duct.
Only a subset of the incident population reaches second-line treatment. ABC-06 reported that 15% to 25% of participants receive second-line therapy, and a United States commercial-claims cohort of 413 participants with advanced biliary tract cancer found that 46% initiated a second line and 16.5% a third line.